Antihypertensive effects of double the maximum dose of valsartan in African-American patients with type 2 diabetes mellitus and albuminuria

Matthew R. Weir, Norman K. Hollenberg, Dion H. Zappe, Xiangyi Meng, Hans Henrik Parving, Giancarlo Viberti, Giuseppe Remuzzi

Research output: Contribution to journalArticlepeer-review

Abstract

OBJECTIVE: The blood pressure (BP)-lowering response to renin-angiotensin-aldosterone system blockade in hypertensive African-Americans is typically less than in whites. To determine whether higher than conventional doses of renin-angiotensin-aldosterone system blockade can improve BP reduction in African-American patients. METHODS: hypertensive patients with type 2 diabetes and albuminuria were enrolled: 110 African-Americans (BP = 150/87 mmHg, aged 57.5 ± 11 years) and 281 non-African-Americans (BP = 151/89 mmHg, aged 57.7 ± 11 years). All patients received valsartan 160 mg once daily in the morning for 4 weeks, following which patients were randomized to receive one of three valsartan doses: 160, 320 or 640 mg/day (2×, maximal recommended dose) for 26 weeks. If at week 6, target BP (

Original languageEnglish
Pages (from-to)186-193
Number of pages8
JournalJournal of Hypertension
Volume28
Issue number1
DOIs
Publication statusPublished - Jan 2010

Keywords

  • African-American
  • Albuminuria
  • Blood pressure
  • Hypertension
  • Valsartan

ASJC Scopus subject areas

  • Internal Medicine
  • Physiology
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Antihypertensive effects of double the maximum dose of valsartan in African-American patients with type 2 diabetes mellitus and albuminuria'. Together they form a unique fingerprint.

Cite this